Rollover Study Protocol for Pediatric Patients in South Africa for Continued Access to Emtricitabine
Status:
Completed
Trial end date:
2017-02-13
Target enrollment:
Participant gender:
Summary
The primary objectives of this trial are to provide FTC-203 study participants in South
Africa with continued access to the study drug, emtricitabine (FTC), following completion of
the FTC-203 study and to collect long-term safety information in participants receiving
emtricitabine in combination with other antiretroviral agents.